tiprankstipranks
Elicio Therapeutics, Inc (DE:9HA)
NASDAQ:9HA
Germany Market
9HA
Elicio Therapeutics
RESEARCH TOOLSreports

Elicio Therapeutics (9HA) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

9HA Analyst Ratings

Strong Buy
4Ratings
Strong Buy
3 Buy
1 Hold
0 Sell
Based on 4 analysts giving stock ratings to
Elicio
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

9HA Stock 12 Month Forecast

Average Price Target

€18.03
▲(71.74% Upside)
Based on 4 Wall Street analysts offering 12 month price targets for Elicio Therapeutics in the last 3 months. The average price target is €18.03 with a high forecast of €23.56 and a low forecast of €10.47. The average price target represents a 71.74% change from the last price of €10.50.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"€5","24":"€24","9.75":"€9.75","14.5":"€14.5","19.25":"€19.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":23.55938703,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€23.56</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.033111059999996,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€18.03</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.47083868,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€10.47</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,9.75,14.5,19.25,24],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.55,10.627645156153847,11.705290312307692,12.782935468461538,13.860580624615384,14.93822578076923,16.01587093692308,17.09351609307692,18.17116124923077,19.248806405384613,20.326451561538462,21.404096717692305,22.481741873846154,{"y":23.55938703,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.55,10.202547004615385,10.855094009230768,11.507641013846154,12.160188018461538,12.812735023076922,13.465282027692307,14.117829032307691,14.770376036923075,15.422923041538459,16.075470046153843,16.72801705076923,17.38056405538461,{"y":18.033111059999996,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.55,9.620833744615386,9.69166748923077,9.762501233846155,9.833334978461538,9.904168723076923,9.975002467692308,10.045836212307693,10.116669956923078,10.187503701538462,10.258337446153845,10.32917119076923,10.400004935384615,{"y":10.47083868,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.15,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.35,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.7,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.85,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.6,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.25,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.8,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.6,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.55,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€23.56Average Price Target€18.03Lowest Price Target€10.47
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Ladenburg Thalmann & Co. Analyst forecast on DE:9HA
Kevin DeGeeter
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
€10.47
Buy
-0.28%
Downside
Initiated
06/18/26
Elicio Therapeutics assumed with a Buy at LadenburgElicio Therapeutics assumed with a Buy at Ladenburg
H.C. Wainwright Analyst forecast on DE:9HA
Robert Burns
H.C. Wainwright
H.C. Wainwright
€20.07
Buy
91.13%
Upside
Reiterated
06/16/26
Elicio Therapeutics price target raised to $23 from $17 at H.C. WainwrightElicio Therapeutics price target raised to $23 from $17 at H.C. Wainwright
JonesTrading Analyst forecast on DE:9HA
Boris Peaker
JonesTrading
JonesTrading
―
Hold
―
Downgraded
06/15/26
Elicio Therapeutics downgraded to Hold from Buy at JonesResearchElicio Therapeutics downgraded to Hold from Buy at JonesResearch
B. Riley Securities Analyst forecast on DE:9HA
Mayank Mamtani
B. Riley Securities
B. Riley Securities
€23.56
Buy
124.38%
Upside
Initiated
06/10/26
Elicio Therapeutics initiated with a Buy at B. RileyElicio Therapeutics initiated with a Buy at B. Riley
Rodman & Renshaw Analyst forecast on DE:9HA
Michael King
Rodman & Renshaw
Rodman & Renshaw
€14.83
Buy
41.27%
Upside
Initiated
03/09/26
Elicio Therapeutics initiated with a Buy at Rodman & RenshawElicio Therapeutics initiated with a Buy at Rodman & Renshaw
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Ladenburg Thalmann & Co. Analyst forecast on DE:9HA
Kevin DeGeeter
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
€10.47
Buy
-0.28%
Downside
Initiated
06/18/26
Elicio Therapeutics assumed with a Buy at LadenburgElicio Therapeutics assumed with a Buy at Ladenburg
H.C. Wainwright Analyst forecast on DE:9HA
Robert Burns
H.C. Wainwright
H.C. Wainwright
€20.07
Buy
91.13%
Upside
Reiterated
06/16/26
Elicio Therapeutics price target raised to $23 from $17 at H.C. WainwrightElicio Therapeutics price target raised to $23 from $17 at H.C. Wainwright
JonesTrading Analyst forecast on DE:9HA
Boris Peaker
JonesTrading
JonesTrading
―
Hold
―
Downgraded
06/15/26
Elicio Therapeutics downgraded to Hold from Buy at JonesResearchElicio Therapeutics downgraded to Hold from Buy at JonesResearch
B. Riley Securities Analyst forecast on DE:9HA
Mayank Mamtani
B. Riley Securities
B. Riley Securities
€23.56
Buy
124.38%
Upside
Initiated
06/10/26
Elicio Therapeutics initiated with a Buy at B. RileyElicio Therapeutics initiated with a Buy at B. Riley
Rodman & Renshaw Analyst forecast on DE:9HA
Michael King
Rodman & Renshaw
Rodman & Renshaw
€14.83
Buy
41.27%
Upside
Initiated
03/09/26
Elicio Therapeutics initiated with a Buy at Rodman & RenshawElicio Therapeutics initiated with a Buy at Rodman & Renshaw
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Elicio Therapeutics

3 Months
Robert BurnsH.C. Wainwright
Success Rate
7/12 ratings generated profit
58%
Average Return
+3.94%
Copying Robert Burns's trades and holding each position for 3 Months would result in 58.33% of your transactions generating a profit, with an average return of +3.94% per trade.
1 Year
Robert BurnsH.C. Wainwright
Success Rate
4/12 ratings generated profit
33%
Average Return
+6.24%
Copying Robert Burns's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +6.24% per trade.
2 Years
Robert BurnsH.C. Wainwright
Success Rate
7/12 ratings generated profit
58%
Average Return
+9.13%
Copying Robert Burns's trades and holding each position for 2 Years would result in 58.33% of your transactions generating a profit, with an average return of +9.13% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

9HA Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
4
3
3
5
8
Buy
0
2
2
2
0
Hold
0
0
0
0
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
4
5
5
7
9
In the current month, 9HA has received 8 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 9HA average Analyst price target in the past 3 months is 18.03.
Each month's total comprises the sum of three months' worth of ratings.

9HA Financial Forecast

9HA Earnings Forecast

Next quarter’s earnings estimate for 9HA is -€0.47 with a range of -€0.52 to -€0.40. The previous quarter’s EPS was -€0.57. 9HA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 9HA has Performed in-line its overall industry.
Next quarter’s earnings estimate for 9HA is -€0.47 with a range of -€0.52 to -€0.40. The previous quarter’s EPS was -€0.57. 9HA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 9HA has Performed in-line its overall industry.

9HA Sales Forecast

Next quarter’s sales forecast for 9HA is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 9HA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 9HA has Performed in-line its overall industry.
Next quarter’s sales forecast for 9HA is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 9HA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 9HA has Performed in-line its overall industry.

9HA Stock Forecast FAQ

What is DE:9HA’s average 12-month price target, according to analysts?
Based on analyst ratings, Elicio Therapeutics, Inc’s 12-month average price target is 18.03.
    What is DE:9HA’s upside potential, based on the analysts’ average price target?
    Elicio Therapeutics, Inc has 71.74% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Elicio Therapeutics, Inc a Buy, Sell or Hold?
          Elicio Therapeutics, Inc has a consensus rating of Strong Buy, which is based on 3 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Elicio Therapeutics, Inc’s share price target?
            The average share price target for Elicio Therapeutics, Inc is 18.03. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €23.56 ,and the lowest forecast is €10.47. The average share price target represents 71.74% Increase from the current price of €10.5.
              What do analysts say about Elicio Therapeutics, Inc?
              Elicio Therapeutics, Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
                How can I buy shares of Elicio Therapeutics, Inc?
                To buy shares of DE:9HA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.